Humanigen Inc (fka HGENQ)

[Knuckle Sandwich]

ACTIV-5 A updated to Active - Not Recruiting.

This was the other NIH Selected Therapeutic of Risankizumab.

“The goal here is to identify as quickly as possible the experimental therapeutics that demonstrate the most clinical promise as COVID-19 treatments and move them into larger-scale testing,” said NIAID Director Anthony S. Fauci, M.D. “This study design is both an efficient way of finding those promising treatments and eliminating those that are not.”

The trial will test risankizumab, a monoclonal antibody developed by Boehringer Ingelheim (Ridgefield, Connecticut) and AbbVie (North Chicago, Illinois), in conjunction with the antiviral drug remdesivir, compared to a placebo plus remdesivir. The ACTIV-5/BET trial will also test the investigational monoclonal antibody lenzilumab, developed by Humanigen (Burlingame, California), with remdesivir, compared to placebo and remdesivir. Remdesivir has demonstrated clinical benefit for patients with severe COVID-19 requiring supplemental oxygen and is considered standard of care for hospitalized COVID-19 patients.

https://clinicaltrials.gov/ct2/history/NCT04583956?A=28&B=29&C=merged#StudyPageTop


https://www.nih.gov/news-events/news-releases/nih-study-aims-identify-promising-covid-19-treatments-larger-clinical-trials